Skip to contentI
Inhibitor Therapeutics, Inc.
I
INTIInhibitor Therapeutics, Inc. Q1 2019 · 10-Q
Revenue$0.00$0.00no prior Q1 2018 on file Net Income-$786.29K-$786.29KN/M vs Q1 2018 EPS Diluted$0.00$0.00— vs Q1 2018 Operating Income-$791,600N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inhibitor Therapeutics, Inc. · CIK 1042418 · Engraved from SEC EDGAR
ended Mar 31, 2019 · filed May 9, 2019 · 39 d after period end